Conference Coverage
about 23 hours ago
In resected RCC, durvalumab/tremelimumab combo bests monotherapy on DFSLatest News
Jun 19, 2026 | Commentary
Sandip Prasad, MD, highlights 3-year data on mitomycin for intravesical solution for LG-IR-NMIBC
The UroOnc Minute: Keeping Patients Engaged in Active Surveillance, With Lourdes Guerrios-Rivera, MD, MSc
Jun 19, 2026
HHS requests testosterone therapy label updates, citing new safety data
Jun 19, 2026
In resected RCC, durvalumab/tremelimumab combo bests monotherapy on DFS
Jun 18, 2026
Andrew J. Armstrong, MD, MSc, discusses study of chemoimmunotherapy in NEPC/AVPC
Jun 18, 2026
Advertisement
Shorts
0:52
Amy E. Krambeck, MD, outlines anatomic enucleation course
a day ago
by
Amy E. Krambeck, MD
1:23
Daniel J. George, MD, on the significance of capivasertib for PTEN-deficient mHSPC
2 days ago
by
Daniel J. George, MD
1:43
What it takes to move the needle on urologic patient safety
3 days ago
by
Matthew Nielsen, MD, MS, FACS
0:42
Why patients choose Break Wave over URS
4 days ago
by
Ben H. Chew, MD, MSc
0:36
Jenny N. Guo, MD, on key BPH takeaways from AUA 2026
8 days ago
by
Jenny N. Guo, MD
0:44
Joy Maulik, CRNP, highlights LUGPA Advanced Practice Provider Forum
9 days ago
by
Joy Maulik, CRNP
1:02
The UroOnc Minute: Patient selection for MDT in the PSMA-PET era
10 days ago
by
Adam B. Weiner, MD(+1 more)
0:55
Archan Khandekar, MD, on the future for AI in urology
11 days ago
by
Archan Khandekar, MD
0:45
Praful Ravi, MB, BChir, MRCP, on residual disease detection using PSMA-PET
14 days ago
by
Praful Ravi, MB, BChir, MRCP
0:28
What BULLSEYE's PFS data should—and shouldn't—mean
15 days ago
by
James Nagarajah, MD
From GSM guidance to HRT reform: A landmark year for women’s health
2025 featured multiple advancements in women's health aimed at enhancing treatment options and awareness.
Inguinal lymph node dissection in penile cancer
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
Inside HoLEP: Irina Jaeger, MD, discusses patient selection and technique
Jaeger emphasizes that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication.
Podcasts
Videos
Urology Times Digital Edition
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
"The overall 0% impact to urology does not help urology practices deal with increasing costs incurred for staff, rent, supplies, and other overhead," write Jonathan Rubenstein, MD, and Mark Painter.
"If 2025 showed us anything, it is the power of combining scientific progress with public engagement," writes Michael S. Cookson, MD, MMHC, FACS.
"Once money is in a Roth IRA, the withdrawal rules depend on whether the funds are contributions, conversions, or earnings," writes Julie Khazan, CFP.
The approval is supported by results from the phase 3 KEYNOTE-905/EV-303 trial.
The ExactVu micro-ultrasound platform demonstrated noninferior detection of clinically significant prostate cancer vs MRI.
"The OBBA includes broad and sweeping changes that will have a profound impact," writes Allan Shen, CFP.
The ENDURE 1 study plans to enroll up to 60 patients with benign ureteric strictures.
The phase 3 PSMAddition trial assessed the combination of 177Lu-PSMA-617 plus ADT/ARPI in an earlier stage of metastatic prostate cancer.
Jaeger emphasized that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication
Continuing Medical Education
Advertisement
All News
Advertisement
The prospective RELIEF study will evaluate the safety and preliminary efficacy of IRE delivered via the NanoKnife System for BPH-related symptoms.
In this episode of Pearls & Perspectives, Thomas F. Stringer, MD, FACS, discusses his journey from private practice to academic urology, his priorities as incoming AUA president, and opportunities to improve men's health engagement and education.
The approval is supported by data from the phase 3 PIVOT-PO trial, in which tebipenem demonstrated noninferiority to imipenem-cilastatin.
Daniel J. George, MD, discusses the clinical significance of the FDA approval of capivasertib, practical considerations for PTEN testing and toxicity management, and the broader implications of precision medicine for patients with advanced prostate cancer.
Jenny Guo, MD, discusses data suggesting that hemi-HoLEP may be a viable treatment option for patients with prior pelvic radiation.
Daniel Eun, MD, discusses the future of reconstructive urology, highlighting the promise of telesurgery and AI-driven surgical technologies while emphasizing the practical barriers that must be addressed for widespread adoption.
Louise Emmett, MD, PhD, MBChB, FRACP, discusses findings from the phase 1 AcTION trial, which evaluated the safety and preliminary activity of 225Ac-PSMA-617 in patients with metastatic castration-resistant prostate cancer.
Toni K. Choueiri, MD, discusses the FDA approval of adjuvant belzutifan plus pembrolizumab for clear cell renal cell carcinoma, describing the regimen as a major advancement in kidney cancer treatment.
Patients who developed ototoxicity during cisplatin treatment experienced less worsening of pure-tone audiometry thresholds in ears treated with ACOU085 compared with placebo-treated ears.
Data from the BREEZE trial support the efficacy, safety, and tolerability of the Zenflow Prostatic Spring for BPH-related LUTS.
Advertisement
The approval is supported by data from the phase 3 CAPItello-281 trial.
The application is supported by data from the phase 3 LITESPARK-022 trial.
In this episode of The UroOnc Minute, Carissa Chu, MD, discusses the prevalence, biology, prognostic significance, and emerging molecular targets of variant histologies in bladder cancer.
In this video, Benjamin H. Lowentritt, MD, FACS, discusses findings from the real-world OPTYX study, assessing testosterone suppression and recovery among patients receiving relugolix for advanced prostate cancer.
Long-term data from the phase 2 TROG 15.03 FASTRACK II trial support the safety and efficacy of stereotactic ablative body radiotherapy for primary renal cell carcinoma.
Advertisement
Advertisement
Trending on Urology Times
1
The ArteraAI Prostate Test: What It Is and How It Works
2
FDA approves tebipenem pivoxil for complicated urinary tract infections
3
HHS requests testosterone therapy label updates, citing new safety data
4
Andrew J. Armstrong, MD, MSc, discusses study of chemoimmunotherapy in NEPC/AVPC
5